Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$9.13 +0.66%

+$0.13 today

Market cap
$821.96M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.30M

Average 1.70M

Returns on capital

Syndax Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-441.6%

avg -100.8%

ROIC

-66.6%

avg -51.8%

ROA

-53.9%

avg -42.6%

Analysis

ROA is currently the strongest return metric at -53.9% versus its period average of -42.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Michael A. Metzger

Chief Executive Officer & DirectorUSD 1.61M550<0.01%

Nicholas Botwood MBBS

Head of Research & Development and Chief Medical OfficerUSD 876.85K58——

Keith Alan Goldan

CFO, Treasurer & Principal Accounting OfficerUSD 852.55K55——

Luke J. Albrecht

General Counsel & Corporate SecretaryUSD 842.31K47——

Steven Closter

Chief Commercial OfficerUSD 822.88K57——

Peter Ordentlich

Co-Founder & Chief Scientific Officer—570<0.01%

Ronald Evans

Co-Founder, Advisor and Chair of Scientific Advisory Board—76——

Averi Price

Senior VP of Legal & Chief Compliance Officer————

Sharon Klahre

Vice President of Investor Relations & Communications————

Michael Downes

Co-Founder————

Richard A. Heyman

Co-Founder—69——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 8, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

10

$2.86M

Net Transaction Value

−$2.86M

Net selling

Most Active

Metzger Michael A

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 29, 26

Podlesak Dennis

Direct

Sell$113.7K
Jul 8, 26

Metzger Michael A

Direct

Sell$784.8K
Jun 12, 26

Botwood Nicholas A.J.

Direct

Sell$566.6K
Jun 11, 26

Botwood Nicholas A.J.

Direct

Sell$617K
Jun 1, 26

Goldan Keith A.

Direct

Sell$22.4K
Jun 1, 26

Metzger Michael A

Direct

Sell$130K
Feb 9, 26

Metzger Michael A

Direct

Sell$360.8K
Feb 9, 26

Goldan Keith A.

Direct

Sell$71.7K
Feb 6, 26

Metzger Michael A

Direct

Sell$152.8K
Feb 6, 26

Goldan Keith A.

Direct

Sell$42.9K

Summary

Insiders reported 0 buys worth $0.00 and 10 sells worth $2.86M over the last 12 months. That adds up to net selling of $2.86M. Metzger Michael A was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
+44.1% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +44.1% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Syndax Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SNDX's management, answered from reported figures.

Who manages SNDX?

Syndax Pharmaceuticals, Inc. (SNDX) lists 11 active executives. The top listed executive is Peter Ordentlich, Co-Founder & Chief Scientific Officer.

Are SNDX insiders buying or selling?

Recent insider activity shows net buying of $50.76M.